New drug combo could shorten histoplasmosis treatment by half
NCT ID NCT07261150
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if a single high dose of an antifungal drug works better than the standard daily dose for treating moderate to severe histoplasmosis, a serious lung infection. It also compares a newer oral drug to the standard one, and checks if 6 months of treatment is as good as 12 months in people with HIV. About 664 hospitalized adults will take part to find safer, more effective ways to control this disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTOPLASMOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Brazil
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States